Eli Lilly Acquires Versanis Bio
July 14, 2023
Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.
- Buyers
- Eli Lilly and Company
- Targets
- Versanis Bio
- Industry
- Biotechnology
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.